3 results
Approved WMORecruiting
To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples
Approved WMORecruiting
Primary ObjectiveTo demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients with aRCC.Secondary Objectives* To demonstrate that…
Approved WMORecruiting
To investigate efficacy of neoadjuvant axitinib and avelumab in patients with localized renal cell carcinoma with moderate to high risk of recurrence .